Anabolic action of parathyroid hormone regulated by the β2-adrenergic receptor

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 19, 2012, Pages 7433-7438

  Hanyu, Ryo ^a,b   Wehbi, Vanessa L ^c   Hayata, Tadayoshi ^a   Moriya, Shuichi ^a,b   Feinstein, Timothy N ^c   Ezura, Yoichi ^a   Nagao, Masashi ^a,b   Saita, Yoshitomo ^a,b   Hemmi, Hiroaki ^a   Notomi, Takuya ^a   Nakamoto, Tetsuya ^a   Schipani, Ernestina ^d   Takeda, Shu ^a   Kaneko, Kazuo ^b   Kurosawa, Hisashi ^b   Karsenty, Gerard ^e   Kronenberg, Henry M ^d   Vilardaga, Jean Pierre ^c   Nodaa, Masaki ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b JUNTENDO UNIVERSITY   (Japan)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e Columbia University ^*  (United States)

Author keywords

Bone anabolism; Bone cells

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; CYCLIC AMP; PARATHYROID HORMONE RECEPTOR; PARATHYROID HORMONE[1-34];

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE ATROPHY; BONE MASS; CONTROLLED STUDY; CORTICAL BONE; FEMALE; GENE EXPRESSION; MOUSE; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PKA; PRIORITY JOURNAL; THYROID HORMONE SYNTHESIS; TRABECULAR BONE;

ABSORPTIOMETRY, PHOTON; ANABOLIC AGENTS; ANIMALS; BONE AND BONES; BONE DENSITY; FEMALE; FEMUR; FLUORESCEINS; GENE EXPRESSION REGULATION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; OSTEOGENESIS; PARATHYROID HORMONE; RECEPTOR, PARATHYROID HORMONE, TYPE 1; RECEPTORS, ADRENERGIC, BETA-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; X-RAY MICROTOMOGRAPHY;

MUS;

EID: 84860826995     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1109036109     Document Type: Article

References (21)

1. Delmas PD (2002) Different effects of antiresorptive therapies on vertebral and nonvertebral fractures in postmenopausal osteoporosis. Bone 30:14-17.
2. Kurland ES, et al. (2000) Parathyroid hormone as a therapy for idiopathic osteoporosis in men: Effects on bone mineral density and bone markers. J Clin Endocrinol Metab 85:3069-3076.
3. Orwoll ES, et al. (2003) The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18:9-17. (Pubitemid 36008334)
4. Sosa Henríquez M, Díez Pérez A (2007) [Parathyroid hormone in the treatment of osteoporosis]. Med Interna 24:87-97.
5. Lindsay R, et al. (1997) Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350:550-555. (Pubitemid 27348431)
6. Cosman F, et al. (2001) Parathyroid hormone added to established hormone therapy: Effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 16:925-931. (Pubitemid 32332303)
7. Keaveny TM, et al. (2008) Femoral bone strength and its relation to cortical and trabecular changes after treatment with PTH, alendronate, and their combination as assessed byfinite element analysis of quantitative CT scans.J BoneMinerRes 23:1974-1982.
8. Saag KG, et al. (2007) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357:2028-2039. (Pubitemid 350106710)
9. Takeda S, et al. (2002) Leptin regulates bone formation via the sympathetic nervous system. Cell 111:305-317. (Pubitemid 35345151)
10. Elefteriou F, et al. (2005) Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 434:514-520. (Pubitemid 40477060)
11. Calvi LM, et al. (2001) Activated parathyroid hormone/parathyroid hormone-related protein receptor in osteoblastic cells differentially affects cortical and trabecular bone. J Clin Invest 107:277-286. (Pubitemid 32157960)
12. Neer RM, et al. (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344: 1434-1441. (Pubitemid 32402100)
13. Calvi LM, Schipani E (2000) The PTH/PTHrP receptor in Jansen's metaphyseal chondrodysplasia. J Endocrinol Invest 23:545-554.
14. McCauley LK, et al. (2001) Parathyroid hormone stimulates fra-2 expression in osteoblastic cells in vitro and in vivo. Endocrinology 142:1975-1981. (Pubitemid 32405955)
15. Ma YL, et al. (2001) Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology 142:4047-4054. (Pubitemid 32802678)
16. Fu Q, Jilka RL, Manolagas SC, O'Brien CA (2002) Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein. J Biol Chem 277:48868-48875. (Pubitemid 35470855)
17. Tyson DR, Swarthout JT, Partridge NC (1999) Increased osteoblastic c-fos expression by parathyroid hormone requires protein kinase A phosphorylation of the cyclic adenosine 3′,5′-monophosphate response element-binding protein at serine 133. Endocrinology 140:1255-1261. (Pubitemid 29104228)
18. Hanyu R, et al. (2011) Per-1 is a specific clock gene regulated by parathyroid hormone (PTH) signaling in osteoblasts and is functional for the transcriptional events induced by PTH. J Cell Biochem 112:433-438.
19. Kondo H, et al. (2005) Unloading induces osteoblastic cell suppression and osteoclastic cell activation to lead to bone loss via sympathetic nervous system. J Biol Chem 280: 30192-30200. (Pubitemid 41216198)
20. Kitahara K, et al. (2003) Osteopontin deficiency induces parathyroid hormone enhancement of cortical bone formation. Endocrinology 144:2132-2140. (Pubitemid 36543353)
21. Chruscinski AJ, et al. (1999) Targeted disruption of the beta2 adrenergic receptor gene. J Biol Chem 274:16694-16700.